ORIGINAL
Utilidad clínica de la cuantificación de infliximab y anticuerpos antiquiméricos humanos
Clinical usefulness in measuring infliximab and human anti-chimeric antibodies
Adriana Rivero Marcoteguia,
, Rosario Ibañez Boschb, Andrés Zuñiga Verab, Antonio Arín Letamendiac, María Jesús Burusco Paternaind
Autor para correspondencia
a Servicio de Bioquímica, Complejo Hospitalario de Navarra, Pamplona, España
b Servicio de Reumatología, Complejo Hospitalario de Navarra, Pamplona, España
c Servicio de Digestivo-A, Complejo Hospitalario de Navarra, Pamplona, España
d Servicio de Digestivo-B, Complejo Hospitalario de Navarra, Pamplona, España
Leído
6380
Vecesse ha leído el artículo
574
Total PDF
5806
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 22 | 6 | 28 |
| 2025 11 | 119 | 25 | 144 |
| 2025 10 | 133 | 18 | 151 |
| 2025 9 | 121 | 9 | 130 |
| 2025 8 | 108 | 12 | 120 |
| 2025 7 | 105 | 6 | 111 |
| 2025 6 | 137 | 10 | 147 |
| 2025 5 | 147 | 5 | 152 |
| 2025 4 | 172 | 4 | 176 |
| 2025 3 | 180 | 11 | 191 |
| 2025 2 | 159 | 11 | 170 |
| 2025 1 | 139 | 3 | 142 |
| 2024 12 | 116 | 10 | 126 |
| 2024 11 | 130 | 3 | 133 |
| 2024 10 | 163 | 8 | 171 |
| 2024 9 | 96 | 7 | 103 |
| 2024 8 | 111 | 2 | 113 |
| 2024 7 | 70 | 5 | 75 |
| 2023 3 | 6 | 0 | 6 |
| 2022 6 | 39 | 2 | 41 |
| 2022 5 | 78 | 7 | 85 |
| 2022 4 | 91 | 17 | 108 |
| 2022 3 | 106 | 18 | 124 |
| 2022 2 | 118 | 9 | 127 |
| 2021 1 | 105 | 8 | 113 |
| 2021 12 | 97 | 14 | 111 |
| 2021 11 | 85 | 13 | 98 |
| 2021 10 | 89 | 16 | 105 |
| 2021 9 | 83 | 13 | 96 |
| 2021 8 | 82 | 13 | 95 |
| 2021 7 | 60 | 10 | 70 |
| 2021 6 | 67 | 6 | 73 |
| 2021 5 | 83 | 9 | 92 |
| 2021 4 | 167 | 6 | 173 |
| 2021 3 | 146 | 8 | 154 |
| 2021 2 | 83 | 7 | 90 |
| 2020 1 | 91 | 12 | 103 |
| 2020 12 | 80 | 10 | 90 |
| 2020 11 | 92 | 9 | 101 |
| 2020 10 | 39 | 8 | 47 |
| 2020 9 | 57 | 15 | 72 |
| 2020 8 | 52 | 7 | 59 |
| 2020 7 | 42 | 11 | 53 |
| 2020 6 | 39 | 7 | 46 |
| 2020 5 | 50 | 11 | 61 |
| 2020 4 | 81 | 2 | 83 |
| 2020 3 | 11 | 2 | 13 |
| 2020 1 | 0 | 2 | 2 |
| 2019 12 | 1 | 0 | 1 |
| 2019 10 | 1 | 0 | 1 |
| 2019 7 | 1 | 2 | 3 |
| 2019 6 | 1 | 0 | 1 |
| 2019 5 | 1 | 2 | 3 |
| 2019 4 | 2 | 0 | 2 |
| 2019 3 | 2 | 2 | 4 |
| 2019 1 | 1 | 0 | 1 |
| 2018 6 | 1 | 0 | 1 |
| 2018 3 | 1 | 0 | 1 |
| 2018 2 | 58 | 0 | 58 |
| 2018 1 | 68 | 0 | 68 |
| 2017 12 | 54 | 0 | 54 |
| 2017 11 | 67 | 2 | 69 |
| 2017 10 | 62 | 1 | 63 |
| 2017 9 | 45 | 1 | 46 |
| 2017 8 | 50 | 0 | 50 |
| 2017 7 | 49 | 1 | 50 |
| 2017 6 | 90 | 17 | 107 |
| 2017 5 | 82 | 1 | 83 |
| 2017 4 | 60 | 3 | 63 |
| 2017 3 | 58 | 33 | 91 |
| 2017 2 | 66 | 1 | 67 |
| 2016 1 | 50 | 1 | 51 |
| 2016 12 | 47 | 4 | 51 |
| 2016 11 | 86 | 8 | 94 |
| 2016 10 | 82 | 3 | 85 |
| 2016 9 | 60 | 7 | 67 |
| 2016 8 | 65 | 6 | 71 |
| 2016 7 | 51 | 5 | 56 |
| 2016 6 | 32 | 14 | 46 |
| 2016 5 | 26 | 8 | 34 |
| 2016 4 | 21 | 10 | 31 |
| 2016 3 | 1 | 2 | 3 |
| 2016 2 | 0 | 1 | 1 |
| 2015 1 | 1 | 0 | 1 |
| 2015 11 | 2 | 0 | 2 |
| 2015 10 | 1 | 1 | 2 |
| 2015 6 | 1 | 0 | 1 |
| 2015 4 | 1 | 0 | 1 |
| 2015 3 | 2 | 1 | 3 |
| 2015 2 | 2 | 0 | 2 |
| 2015 1 | 0 | 2 | 2 |
| 2014 11 | 0 | 1 | 1 |
| 2014 10 | 2 | 1 | 3 |
| 2014 9 | 1 | 1 | 2 |
| 2014 8 | 1 | 2 | 3 |
| 2014 7 | 3 | 3 | 6 |
Mostrar todo
